Effects of Interleukin (IL)-17A Inhibition on Idiopathic Subglottic Stenosis

Description

The purpose of this phase 2 study is to examine if inhibiting IL-17A activation using the biologic drug Taltz, in idiopathic subglottic stenosis patients will decrease scar fibroblast proliferation therefore reducing or eliminating the need for invasive or repeat surgeries.

Conditions

Idiopathic Subglottic Stenosis

Talk to us

Study Overview

On this page

Study Details

Study overview

The purpose of this phase 2 study is to examine if inhibiting IL-17A activation using the biologic drug Taltz, in idiopathic subglottic stenosis patients will decrease scar fibroblast proliferation therefore reducing or eliminating the need for invasive or repeat surgeries.

Effects of IL-17A Inhibition on Idiopathic Subglottic Stenosis

Effects of Interleukin (IL)-17A Inhibition on Idiopathic Subglottic Stenosis

Condition
Idiopathic Subglottic Stenosis
Intervention / Treatment

-

Contacts and Locations

New Haven

Yale New Haven Hospital, New Haven, Connecticut, United States, 06520

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Provision of signed and dated informed consent form
  • * Stated willingness to comply with all study procedures and availability for the duration of the study
  • * diagnosis of idiopathic subglottic stenosis
  • * History of active or latent tuberculosis infection
  • * History of inflammatory bowel disease
  • * Pregnancy or lactation
  • * Known allergic reactions to study drug
  • * Disease involving the vocal cords
  • * Individuals who are taking drugs known to trigger angioedema, including use acquired angioedema from drugs such as ACE inhibitors (e.g. Lisinopril) and nonsteroidal anti-inflammatory drugs (NSAIDs) and individuals with a history of other forms of angioedema such as hereditary and Clesterase deficiency

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Yale University,

Nwanmegha Young, MD, PRINCIPAL_INVESTIGATOR, Yale University

Study Record Dates

2026-04